Pfizer Inc
In its 13F for Q2 2025 (holdings as of June 30, 2025, filed August 11, 2025), Pfizer Inc reported 21 stock positions worth $576.2 million. Its top holding was Biontech SE-ADR (BNTX) at 67.6% of the portfolio, followed by Oric Pharmaceuticals (ORIC, 9.5%) and Arvinas (ARVN, 4.4%). Compared with Q1 2025, it reduced 1. The biggest sale was Nextcure (NXTC, shares −92%).
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0000078003
- Portfolio Value
- $576.2M (Q2 2025)
- SEC Filing
- 0000078003-25-000142 ↗ filed Aug 11, 2025
Holdings Value
Holdings 21 stocks · $576.2M
| BNTX Biontech SE-ADR | 67.60% | 3,658,361 | $389.5M | No change |
| ORIC Oric Pharmaceuticals Inc. | 9.47% | 5,376,344 | $54.6M | No change |
| ARVN Arvinas Inc. | 4.42% | 3,457,815 | $25.4M | No change |
| ALLO Allogene Therapeutics Inc. | 4.32% | 22,032,040 | $24.9M | No change |
| TRML Tourmaline Bio Inc. | 3.53% | 1,272,214 | $20.3M | No change |
| WVE Wave Life Sciences Ltd. | 2.12% | 1,875,000 | $12.2M | No change |
| PYXS Pyxis Oncology Inc. | 1.34% | 7,032,770 | $7.7M | No change |
| CRDF Cardiff Oncology Inc. | 1.32% | 2,411,575 | $7.6M | No change |
| BHVN Biohaven Ltd. | 1.24% | 505,645 | $7.1M | No change |
| SPRO Spero Therapeutics Inc. | 1.19% | 2,362,348 | $6.9M | No change |
| CRBU Caribou Biosciences Inc. | 1.03% | 4,690,431 | $5.9M | No change |
| CELC Celcuity Inc. | 0.81% | 349,406 | $4.7M | No change |
| ZURA Zura Bio Ltd. | 0.54% | 2,970,022 | $3.1M | No change |
| EPIX Essa Pharma Inc. | 0.49% | 1,675,000 | $2.8M | No change |
| ZNTL Zentalis Pharmaceuticals Inc. | 0.19% | 953,834 | $1.1M | No change |
| NXTC Nextcure Inc. | 0.15% | 157,646 | $870K | Reduce -91.7% |
| ANTX AN2 Therapeutics Inc. | 0.13% | 715,295 | $758K | No change |
| QTTB Q32 Bio Inc. | 0.07% | 277,777 | $414K | No change |
| BOLT Bolt Biotherapeutics Inc. | 0.03% | 31,305 | $181K | No change |
| DNA Ginkgo Bioworks Holdings Inc. | 0.01% | 2,928 | $33K | No change |
| SENS Senseonics Holdings Inc. | 0.00% | 43,426 | $21K | No change |
Portfolio Sells Q1 2025 → Q2 2025
| NXTC Nextcure Inc. | Reduce -91.7% | 0.15% | −0.03 |
Portfolio Buys Q1 2025 → Q2 2025
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 17 | $170.4M | ALLO, CELC, ARVN, PYXS, WVE |
| Q1 2026 | 18 | $238.8M | ORIC, ALLO, ARVN, CELC, ZURA |
| Q4 2025 | 18 | $236.5M | ORIC, ARVN, CELC, WVE, ALLO |
| Q3 2025 | 21 | $437.5M | BNTX, ORIC, TRML, ARVN, ALLO |
| Q2 2025 | 21 | $576.2M | BNTX, ORIC, ARVN, ALLO, TRML |
| Q1 2025 | 21 | $500.8M | BNTX, ALLO, ORIC, ARVN, TRML |
| Q4 2024 | 23 | $2.6B | HLN, BNTX, ARVN, ALLO, ORIC |